Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal Cancer Grant

Pfizer is offering a competitive grants program aimed at enhancing healthcare professionals' understanding of BRAF V600E-mutant metastatic colorectal cancer treatment. This initiative focuses on advancing knowledge of clinical data, optimizing treatment protocols, and promoting biomarker testing in community settings. Eligible organizations, including medical institutions and education providers, can apply for funding to support educational projects that address these key areas, ultimately improving patient outcomes in this critical area of cancer care.

Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal Cancer
General Area of Interest for this RFP:
Projects that will be considered for Pfizer support will focus on increasing healthcare professional’s understanding and competence in one or more of the following areas:
Increase understanding and awareness of the latest clinical data updates and guideline recommendations relevant to the first line treatment of patients with BRAF V600E-mutant mCRC and mNSCLC.Optimize BRAF inhibitor-based treatment for BRAF V600E-mutant mCRC and mNSCLC through proper management of adverse events through dose modifications and supportive care.Increase awareness of BRAF V600E biomarker testing and first-line treatment options in mCRC and mNSCLC in the community setting.Maximize therapy management strategies of BRAF inhibitor combination therapies through collaboration between experts in academic centers and community oncologists.

Eligibility

Applicant organizations to this RFP must be based in United States
The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to patient and/or healthcare professional education and/or healthcare improvement.Only organizations are eligible to receive grants, not individuals or physician-owned medical practices. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role, and the requesting organization must have a key role in the project. Examples of educational formats that will be considered under this RFP include but are not limited to:
Creative educational initiatives with the potential for wide-reaching engagement.Education using online platforms with downloadable resources and reference tools for HCPs and/or patients.Professional medical society programs with wide reach to community oncologists caring for patients being treated for BRAF V600E-mutant mCRC and mNSCLC in the first line setting.Interactive learnings, case-based learnings, workshops, tumor boards.Online articles, training courses, webinars.Social media posted & linked content.Videos, podcasts, infographics, animations.

Ineligibility

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.